Aviir’s TruRisk technology consists of a blood test that measures the blood levels of 7 proteins associated with the development of unstable plaque.
It then uses a complex algorithm to analyze those results and known risk factors to determine an individual’s probability of experiencing a heart attack within the next five years.
Aviir CEO Douglas Harrington said the company intends to determine and prevent cardiovascular diseases through proprietary blood tests and treatment plan recommendations.
The financing includes an initial investment of $10m and future investments of up to $20m upon achieving certain milestones.
The financing round was led by Merck Global Health Innovation Fund and other investors like Bay City Capital, Aberdare Ventures, New Leaf Venture Partners also participated.